{"id":8611,"date":"2021-05-14T09:13:00","date_gmt":"2021-05-14T09:13:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=8611"},"modified":"2024-05-02T10:02:04","modified_gmt":"2024-05-02T08:02:04","slug":"successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/","title":{"rendered":"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis"},"content":{"rendered":"
\n

Miho Hatanaka<\/a>\u00a01<\/a><\/sup>,\u00a0Kazuyasu Fujii<\/a>\u00a01<\/a><\/sup>,\u00a0Takuro Kanekura<\/a>\u00a01<\/a><\/sup> J Dermatol<\/a>\u00a02021 Aug;48(8):e376-e377.\u00a0doi: 10.1111\/1346-8138.15946.\u00a0 <\/p>\n<\/div>\n\n

\n

Pyoderma gangrenosum (PG), acne(A), and Suppurative hidradenitis (SH) syndrome (PASHs) is a recently proposed disease entity clinically characterized by PG, acne, and SH, belonging to the spectrum of hereditary autoinflammatory syndrome with PG. Although biologic agents targeting interleukin-1 and tumor necrosis factor-\u03b1 have been recommended for the treatment of PASHs, their efficacy has not been well established because of its rarity.
Granulocyte and monocyte adsorption apheresis is an extracorporeal apheresis unit designed to selectively remove pathogenic granulocytes and macrophages that produce proinflammatory cytokines. The efficacy of GMA on PG has been reported, and treatment of PASHs with GMA has been described in a single case report<\/p>\n<\/div>\n\n

\n

Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis – PubMed (nih.gov)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Miho Hatanaka\u00a01,\u00a0Kazuyasu Fujii\u00a01,\u00a0Takuro Kanekura\u00a01 J Dermatol\u00a02021 Aug;48(8):e376-e377.\u00a0doi: 10.1111\/1346-8138.15946.\u00a0 Pyoderma gangrenosum (PG), acne(A), and Suppurative hidradenitis (SH) syndrome (PASHs) is a recently proposed disease entity clinically characterized by PG, acne, and SH, belonging to the spectrum of hereditary autoinflammatory syndrome with PG. Although biologic agents targeting interleukin-1 and tumor necrosis factor-\u03b1 have been recommended for the […]<\/p>\n","protected":false},"template":"","scientific_tags":[127,307,157,424,115,156,128],"class_list":["post-8611","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-acne","scientific_tags-dermatology","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-pyoderma-gangrenosum","scientific_tags-safety","scientific_tags-suppurative-hidradenitis"],"acf":{"sc_authors":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33991008\/<\/a>"},"yoast_head":"\nSuccessful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Miho Hatanaka\u00a01,\u00a0Kazuyasu Fujii\u00a01,\u00a0Takuro Kanekura\u00a01 J Dermatol\u00a02021 Aug;48(8):e376-e377.\u00a0doi: 10.1111\/1346-8138.15946.\u00a0 Pyoderma gangrenosum (PG), acne(A), and Suppurative hidradenitis (SH) syndrome (PASHs) is a recently proposed disease entity clinically characterized by PG, acne, and SH, belonging to the spectrum of hereditary autoinflammatory syndrome with PG. Although biologic agents targeting interleukin-1 and tumor necrosis factor-\u03b1 have been recommended for the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T08:02:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/\",\"name\":\"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2021-05-14T09:13:00+00:00\",\"dateModified\":\"2024-05-02T08:02:04+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/","og_locale":"fr_FR","og_type":"article","og_title":"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte","og_description":"Miho Hatanaka\u00a01,\u00a0Kazuyasu Fujii\u00a01,\u00a0Takuro Kanekura\u00a01 J Dermatol\u00a02021 Aug;48(8):e376-e377.\u00a0doi: 10.1111\/1346-8138.15946.\u00a0 Pyoderma gangrenosum (PG), acne(A), and Suppurative hidradenitis (SH) syndrome (PASHs) is a recently proposed disease entity clinically characterized by PG, acne, and SH, belonging to the spectrum of hereditary autoinflammatory syndrome with PG. Although biologic agents targeting interleukin-1 and tumor necrosis factor-\u03b1 have been recommended for the […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T08:02:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/","name":"Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2021-05-14T09:13:00+00:00","dateModified":"2024-05-02T08:02:04+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/successful-treatment-of-pyoderma-gangrenosum-acne-and-suppurative-hidradenitis-syndrome-with-granulocyte-and-monocyte-adsorption-apheresis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/8611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=8611"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=8611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}